CRISPR Therapeutics AG logo

CRSP: CRISPR Therapeutics AG

Stock

About

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Website
www.crisprtx.com
Year Founded
2013
Employees
407
Sector
Health Care
HQ Location
Zug, undefined

Current Value

$49.00

1 Year Return

-$11.51
-19.02%

Key Details

Market Cap

$4.16B

P/E Ratio

-17.24

1Y Stock Return

-16.24%

1Y Revenue Growth

19.31%

Dividend Yield

0.00%

Price to Book

2.1

Strategies that include
CRSP

High risk

$1,200

0.43%

Growth at a Fair Price

speculation
maximum growth

These stocks above $1B in Market Cap are modestly valued (PE below 15) but are in the top 20% of stocks for revenue growth over the past 5 years. We weight them by market cap.

Top Sector

Health Care

Top Holdings

HubSpot Inc logo
Lemonade Inc logo
Flutter Entertainment Plc logo
Armada Hoffler Properties Inc logo
First Citizens Bancshares, Inc (NC) - Ordinary Shares - Class A logo

Return

+27.15%

Expense Ratio

0.00%

Holdings

231

Medium risk

$13,000

0.07%

Health Care Sector

growth
balanced
growth income

This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.

Top Sector

Health Care

Top Holdings

Lilly(Eli) & Co logo
Unitedhealth Group Inc logo
Abbvie Inc logo
Johnson & Johnson logo
Merck & Co Inc logo

Return

+8.88%

Expense Ratio

0.00%

Holdings

330

High risk

$1,000

4.45%

ARK Innovation ETF

speculation
maximum growth

The ARKK fund was designed to seek long term capital from companies globally involved with, or that benefit from, disruptive innovation.

Top Sector

Health Care

Top Holdings

Tesla Inc logo
Coinbase Global Inc - Ordinary Shares - Class A logo
Roku Inc - Ordinary Shares - Class A logo
Roblox Corporation - Ordinary Shares - Class A logo
Palantir Technologies Inc - Ordinary Shares - Class A logo

Return

+5.97%

Expense Ratio

0.00%

Holdings

30

Create your own
strategy with

CRSP
Three dimensional double logo

Stock's related to
CRSP

ETF's related to
CRSP

News

Yahoo

We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other worst ARK stocks to buy according to short sellers. Cathie Wood of ARK Investment is one of Wall Street’s most well-known hedge […]

SeekingAlpha

Vertex Pharmaceuticals Incorporated looks set for two new drug approvals in early 2025. Click here to read an analysis of VRTX stock now.

SeekingAlpha

uniQure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges despite strong clinical data.

Yahoo

-Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol- -Company announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX112 for the treatment of certain relapsed or refractory (R/R) CD19-positive B-cell malignancies- -CTX112 is also in a Phase 1 clinical trial in systemic lupus erythematosus (SLE),

Yahoo

The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500. Despite moving in opposite directions in 2024, CRISPR Therapeutics and Exelixis have strong prospects.

Yahoo

CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Disclaimer

Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.

Zero Expense Ratio Index Investing

Company

DisclosuresLinkedInX

Resources

BlogLearnFee CalculatorTax Bracket Estimator

© Double Finance, 2024

Double is a registered investment adviser with the US Securities and Exchange Commission (SEC). While such registration does not imply a certain level of skill, it does require us to follow federal regulations that protect you, the investor. By law, we must provide investment advice that is in the best interest of our client. Please refer to Double's Form CRS for important additional information.

The publicly available portions of the Platform (i.e., the sections of the Platform that are available to individuals who are not party to a Client Agreement - including double.finance) are provided for educational purposes only and are not intended to provide legal, tax, or financial planning advice. To the extent that any of the content published on publicly available portions of the Platform may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person. Nothing on the publicly available portions of the Platform should be construed as a solicitation or offer, or recommendation, to buy or sell any security. All charts, figures, and graphs on the publicly available websites are for illustrative purposes only. Before investing, you should consider whether any investment, investment strategy, security, other asset, or related transaction is appropriate for you based on your personal investment objectives, financial circumstances, and risk tolerance. You are also encouraged to consult your legal, tax, or investment professional regarding your specific situation. Registration does not imply a certain level of skill or training.

Investing involves risk. The value of your investment will fluctuate, and you may gain or lose money.

The contents of the Platform may contain forward-looking statements that are based on management's beliefs, assumptions, current expectations, estimates, and projections about the financial industry, the economy, or Global Predictions itself. Forward-looking statements are not guarantees of the underlying expected actions or future performance and future results may differ significantly from those anticipated by the forward-looking statements. Therefore, actual results and outcomes may materially differ from what may be expressed or forecasted in such forward-looking statements.

¹ Data as of July 2024.

² Availability of tax loss harvesting depends on portfolio diversity.

³ As of November 8, 2024. The optional Cash Sweep program takes the cash sitting in your brokerage account and moves it to an FDIC-insured interest-earning deposit account. The current yield is 1.0%, rates subject to change at any time. The cash sweep program is made available in coordination with Apex Clearing Corporation. Please read the Important Disclosures for more information.

⁴ This analysis calculator tool is for illustrative purposes only and is not financial advice. We do not guarantee the accuracy of the results or their relevance to your particular circumstances. This calculator uses hypothetical historical data and does not take into account the effect of taxes on a taxable account. Hypothetical historical data is no guarantee of future performance and this calculator is not intended to predict actual performance. The input of different time periods, amounts, and fees will vary calculator results. Average ETF fee is based on the AUM weighted average of US ETFs as of September 2024, see more information. Note that you can purchase ETFs through Double, which may incur additional fees.

Full pricing details along with an FAQ can be found here

Data displayed in charts and graphics above are for illustrative purposes only and do not reflect actual investment results and are not a guarantee of future results.

By using double.finance, you accept our and . Double is only available to US residents.

See Double Finance Form ADV Part IIA for additional information. Double does not guarantee that the results of its advice, recommendations, or the objectives of its direct index or cash management strategies will be achieved. We make no assurance that the investment process will consistently lead to successful investing. Before you invest, you should carefully review and consider your investment objectives as well as the risks, charges, and expenses of the underlying securities. There is at least a $1,000 account minimum required to participate in Double's strategies, although some strategies may have higher minimums.

Double does not provide tax, or legal advice. Double's website, brokerage, and advisory services are not intended for persons of any jurisdiction where Double is not authorized to do business. Tax savings will vary from client to client due to many factors including market conditions, tax characteristics of securities, client-imposed investment restrictions, client tax rate or status, and changes in tax regulations.